![](images/null.gif) |
![](images/null.gif) |
![](images/null.gif) |
|
Significant anti-fibrotic efficacy of EDP-305, a highly potent and selective farnesoid X receptor (FXR) agonist, in a rat model of thioacetamide-induced liver fibrosis and cirrhosis
|
|
|
Reported by Jules Levin
AASLD Annual Meeting 2017, Washington, DC, USA, October 20-24
Li-Juan Jiang1,*, Dipankar Bhattacharya2, Young J. Yoon2, Hsin-I Chou2, Mary Chau1, Yang Li1, Yat Sun Or1, Scott L. Friedman2
1 Enanta Pharmaceuticals, Inc., Watertown, MA, USA; 2 Icahn School of Medicine at Mount Sinai, New York, NY, USA
![1120171](../images/112017/112017-7/1120171.gif)
![1120172](../images/112017/112017-7/1120172.gif)
![1120173](../images/112017/112017-7/1120173.gif)
![1120174](../images/112017/112017-7/1120174.gif)
![1120175](../images/112017/112017-7/1120175.gif)
![1120176](../images/112017/112017-7/1120176.gif)
|
|
|
![](images/null.gif) |
![](images/null.gif) |
|
|